Your browser doesn't support javascript.
loading
X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
Kallen, Joerg; Bergsdorf, Christian; Arnaud, Bertrand; Bernhard, Mario; Brichet, Murielle; Cobos-Correa, Amanda; Elhajouji, Azeddine; Freuler, Felix; Galimberti, Ivan; Guibourdenche, Christel; Haenni, Simon; Holzinger, Sandra; Hunziker, Juerg; Izaac, Aude; Kaufmann, Markus; Leder, Lukas; Martus, Hans-Joerg; von Matt, Peter; Polyakov, Valery; Roethlisberger, Patrik; Roma, Guglielmo; Stiefl, Nikolaus; Uteng, Marianne; Lerchner, Andreas.
Afiliação
  • Kallen J; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Bergsdorf C; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Arnaud B; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Bernhard M; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Brichet M; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Cobos-Correa A; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Elhajouji A; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Freuler F; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Galimberti I; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Guibourdenche C; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Haenni S; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Holzinger S; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Hunziker J; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Izaac A; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Kaufmann M; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Leder L; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Martus HJ; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • von Matt P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Polyakov V; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Roethlisberger P; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Roma G; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Stiefl N; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Uteng M; Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
  • Lerchner A; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.
ChemMedChem ; 13(18): 1997-2007, 2018 09 19.
Article em En | MEDLINE | ID: mdl-29985556

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Proteínas Serina-Treonina Quinases / Transtornos Cromossômicos / Inibidores de Proteínas Quinases / Indazóis Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Proteínas Serina-Treonina Quinases / Transtornos Cromossômicos / Inibidores de Proteínas Quinases / Indazóis Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article